<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01880346</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00066261</org_study_id>
    <secondary_id>Hermes vitamin D</secondary_id>
    <nct_id>NCT01880346</nct_id>
  </id_info>
  <brief_title>Comparison of Absorption of Vitamin D in Cystic Fibrosis</brief_title>
  <official_title>Vehicles for the Absorption of Vitamin D in Cystic Fibrosis: Comparison of Powder vs Oil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators predict that a powder pill form of vitamin D will be more effectively
      absorbed than an oil form of vitamin D in people diagnosed with Cystic Fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to see how well two different forms of vitamin D work in Cystic
      Fibrosis (CF). Patients with Cystic Fibrosis have a hard time absorbing certain foods and
      often have low vitamin D levels. Studies show that vitamin D may help fight infections common
      in Cystic Fibrosis. The investigators would like to see if a powder pill form of vitamin D
      will work better than a pill mixed with oil. Each person will randomly receive either a
      powder pill or an oil based pill. Blood will be tested while during a 3-4 day hospital stay.
      The investigators plan to enroll no more than 24 patients with CF from Emory University
      Hospital for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Absorption of vitamin D3 to blood</measure>
    <time_frame>72 hours</time_frame>
    <description>rates of absorption of D3 will be compared for either an oil based or powder form pill OVER 72 HOURS.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>100,000 IU D-50 powder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D oil vs powder. 100,000 IU powder form of vitamin D, assessment of D3 absorption. One Dose of vitamin D powder format administered. Absorption rate monitored over 72 hour period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100,000 IU Maximum D3 in oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D oil vs powder. One Dose of 100,000 IU vitamin D oil format administered. Absorption rate monitored over 72 hour period</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D Powder</intervention_name>
    <description>Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing</description>
    <arm_group_label>100,000 IU D-50 powder</arm_group_label>
    <other_name>D3-50 Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D Oil</intervention_name>
    <description>Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing</description>
    <arm_group_label>100,000 IU Maximum D3 in oil</arm_group_label>
    <other_name>Maximum D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult CF patients (age &gt;18 years

          -  Able to tolerate oral medication

          -  Expected to survive the duration of the study

        Exclusion Criteria:

          -  Inability to obtain or declined informed consent from the subject and/or legally
             authorized representative

          -  History of disorders associated with hypercalcemia

          -  Current hypercalcemia (albumin-corrected serum calcium &gt;10.8 mg/dL or ionized calcium
             &gt;5.2 mg/dL)

          -  Chronic kidney disease worse than stage III (&lt;60 ml/min), 7) Forced Expiratory Volume
             (FEV1)% predicted &lt;20%

          -  Current significant hepatic dysfunction total bilirubin &gt; 2.5 mg/dL with direct
             bilirubin &gt; 1.0 mg/dL

          -  Current use of cytotoxic or immunosuppressive drugs

          -  History of AIDS or illicit drug abuse

          -  too ill to participate in study based on investigator's or study team's opinion

          -  current enrollment in another intervention trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vin Tangpricha, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Grossmann RE, Zughaier SM, Liu S, Lyles RH, Tangpricha V. Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. Eur J Clin Nutr. 2012 Sep;66(9):1072-4. doi: 10.1038/ejcn.2012.82. Epub 2012 Jul 18.</citation>
    <PMID>22805498</PMID>
  </results_reference>
  <results_reference>
    <citation>Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, Marshall BC, Borowitz D; Cystic Fibrosis Foundation Vitamin D Evidence-Based Review Committee. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012 Apr;97(4):1082-93. doi: 10.1210/jc.2011-3050. Epub 2012 Mar 7.</citation>
    <PMID>22399505</PMID>
  </results_reference>
  <results_reference>
    <citation>Tangpricha V, Koutkia P, Rieke SM, Chen TC, Perez AA, Holick MF. Fortification of orange juice with vitamin D: a novel approach for enhancing vitamin D nutritional health. Am J Clin Nutr. 2003 Jun;77(6):1478-83.</citation>
    <PMID>12791627</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnson EJ, Krasinski SD, Howard LJ, Alger SA, Dutta SK, Russell RM. Evaluation of vitamin A absorption by using oil-soluble and water-miscible vitamin A preparations in normal adults and in patients with gastrointestinal disease. Am J Clin Nutr. 1992 Apr;55(4):857-64.</citation>
    <PMID>1550069</PMID>
  </results_reference>
  <results_reference>
    <citation>Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol (1985). 1993 Dec;75(6):2419-24.</citation>
    <PMID>8125859</PMID>
  </results_reference>
  <results_reference>
    <citation>Hecker TM, Aris RM. Management of osteoporosis in adults with cystic fibrosis. Drugs. 2004;64(2):133-47. Review.</citation>
    <PMID>14717616</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>June 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Vin Tangpricha, MD, PH.D</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>absorption</keyword>
  <keyword>vitamin Deficiency</keyword>
  <keyword>fat soluble</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

